App-Quantinova.ai

Prediction of malignant progression of Barretts oesophagus: A complete systematic review and meta-analysis.

Kiran Altaf - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Efficacy and safety of rhLT-Da with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-labelled, controlled, phase IIb trial.

Yu-hong Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Fluorouracil

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: Capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).

Yan Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic gastric and oesogastric junction (AGC) adenocarcinoma

Capecitabine and oxaliplatin

Phase III randomized study of elective nodal irradiation plus erlotinib combined with chemotherapy for esophageal squamous cell carcinoma.

Shi Xiu Wu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Erlotinib hydrochloride

Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel as first-line chemotherapy for patients with metastatic gastric cancer.

Rui-hua Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Protein-bound paclitaxel

Prospective randomized phase II study of concurrent chemoradiotherapy versus chemotherapy alone in stage IV esophageal squamous cell carcinoma.

Tao Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

How many lymph nodes should be removed to define an optimal D2 lymphadenectomy for gastric cancer in the modern era? An analysis of 2,947 patients from a two-institution database in China.

Changming Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Comparison of cooled-probe microwave and radiofrequency ablation treatment in incipient hepatocellular carcinoma: A phase randomized controlled trial with 6-year follow-up.

Jie Yu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).

Shukui Qin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Tepotinib

A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Tawesak Tanwandee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Capmatinib

Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.

Bruno Sangro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

A Prospective Multicenter Phase II Study of Sorafenib Combined with Cisplatin plus Gemcitabine for the Treatment of Patients with Advanced Renal Collecting Duct Carcinoma (NCT01762150).

Xinan Sheng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Collecting duct carcinoma

Gemcitabine

Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.

Ai-Ping Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

anlotinib

Radiation plus concurrent nimotuzumab versus CDDP in locally advanced nasopharyngeal cancer: Results of a phase III randomised trial.

Lin Kong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

Nimotuzumab

Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.

Li Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

Gemcitabine

Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma.

Yongkun Sun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Medullary thyroid carcinoma

anlotinib

Response to induction chemotherapy for locally advanced nasopharyngeal cancer to predict prognostic impact of chemosensitivity.

Jiade J. Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

Gemcitabine

Prognostic value of plasma fibrinogen level and cervical nodal necrosis in stage IVA/b nasopharyngeal carcinoma patients who had positive cervical nodal metastasis.

Mei Lan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

Fibrinogen (IV)

Molecular decision tree algorithms to predict individual recurrence pattern for locally advanced nasopharyngeal carcinoma.

Xiang Bo Wan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

N/A

A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy.

Chang-Juan Tao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

N/A

Filters

24782 Abstracts